Has Swati Yalamanchi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $19,459 in general payments to Swati Yalamanchi, MD across 437 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Swati Yalamanchi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Swati Yalamanchi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Swati Yalamanchi, MD

Hematology & Oncology · Corbin, KYNPI 1023243144

Payments from drug & device makers

$19,459in general payments, 2019–2025

Across 437 payments — averaging $44.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$10K
Johnson & Johnson$1K
Novartis$740
AstraZeneca$585
Merck$583
E.r. Squibb & Sons, L.L.C.$477
plus $6K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	19	$10,313
Johnson & Johnson(2 entities)	44	$1,240
Novartis	29	$740
AstraZeneca(2 entities)	27	$585
Merck	31	$583
E.r. Squibb & Sons, L.L.C.	31	$477
Amgen	17	$362
Incyte Corporation	11	$334
Daiichi Sankyo Inc.	19	$325
Bristol Myers Squibb	16	$320
Sanofi	15	$315
Regeneron Healthcare Solutions, Inc.	10	$252
Pharmacyclics LLC, An Abbvie Company	7	$232
Jazz Pharmaceuticals Inc.	7	$226
Genmab U.S., Inc.	10	$192
Astellas Pharma US Inc	10	$188
AbbVie	9	$182
Genentech USA, Inc.	11	$179
Gilead(2 entities)	9	$168
Seagen Inc.	9	$167
Acrotech Biopharma Inc.	1	$125
GSK	6	$124
Dova Pharmaceuticals	1	$118
Exelixis Inc.	2	$114
EMD Serono, Inc.	4	$107
Takeda Pharmaceuticals U.S.A., Inc.	5	$103
Coherus Oncology, Inc.	4	$96
Rigel Pharmaceuticals, Inc.	6	$86
Stemline Therapeutics Inc.	4	$86
AVEO Pharmaceuticals, Inc.	5	$86
Beone Medicines USA, Inc.	3	$85
Pharmacosmos Therapeutics Inc.	5	$75
Ipsen Biopharmaceuticals, Inc	4	$72
Lilly USA, LLC	4	$64
Bayer	4	$64
Karyopharm Therapeutics Inc.	3	$63
Cumberland Pharmaceuticals, Inc.	3	$61
Boehringer Ingelheim	3	$47
Beigene USA, Inc.	2	$45
Array Biopharma Inc	4	$43
Sobi, Inc	2	$42
ADC Therapeutics America, Inc.	2	$37
Tesaro, Inc.	2	$28
Morphosys, US Inc.	2	$28
Tosoh Bioscience, Inc.	1	$25
Eisai Inc.	1	$23
Progenics Pharmaceuticals, Inc.	1	$23
Sun Pharmaceutical Industries Inc.	1	$23
Clovis Oncology, Inc.	2	$23
Pharmaessentia USA Corporation	1	$23
Verastem, Inc.	1	$21
Agios Pharmaceuticals, Inc.	1	$20
Blueprint Medicines Corporation	1	$18
G1 Therapeutics, Inc.	1	$18
Iovance Biotherapeutics, Inc.	1	$17
AMAG Pharmaceuticals, Inc.	1	$17
Taiho Oncology, Inc.	1	$15
Puma Biotechnology, Inc.	1	$14

How this compares

$19,459 in reported general payments places this provider in the 60th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$50,460

Medicare patients

110

Services billed

727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Corbin

Joseph MalyLouisville$7M
Firas BadinLexington$6.7M
Laila AgrawalLouisville$6.3M
Jaspreet GrewalLouisville$4.2M
John VillanoLexington$3.2M
Rebecca RedmanLouisville$2.1M
Vivek SharmaLouisville$1.9M
Rohit KumarLouisville$1.6M
Miguel Islas-OhlmayerEdgewood$1.6M
Jeffrey HargisLouisville$1.3M

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →